Loading...
Loading...
JAZZ| Name | Value |
|---|---|
| Revenues | 1,011.9M |
| Cost of Revenue | 258.8M |
| Gross Profit | 753.1M |
| Operating Expense | 550.9M |
| Operating I/L | 202.2M |
| Other Income/Expense | -61.0M |
| Interest Income | 20.7M |
| Pretax | 61.5M |
| Income Tax Expense | -33.1M |
| Net Income/Loss | 94.2M |
Jazz Pharmaceuticals plc is a biopharmaceutical company that focuses on identifying, developing, and commercializing pharmaceutical products for unmet medical needs in the areas of neuroscience and oncology. The company's portfolio includes products such as Xyrem, Sunosi, Erwinaze, Defitelio, Vyxeos liposome, and Zepzelca, addressing conditions like narcolepsy, sleep disorders, leukemia, and small cell lung cancer. Additionally, Jazz Pharmaceuticals has a pipeline of product candidates, including Xywav, JZP-324, JZP385, JZP458, and JZP150, targeting various medical conditions. The company generates revenue through the sales of its marketed products and potential future commercialization of its product candidates.
